Mirdametinib in Patients With Advanced NF1-mutant Melanoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Mirdametinib in Patients With Advanced NF1-mutant Melanoma — Stella

Recruiting

Back to Advanced Unresectable Melanoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

California Pacific Medical Center - Sutter Health, San Francisco, California

Key details

Phase

Safety & dosing

Sponsor

Kevin Kim, MD

Enrollment target

~10 participants

Started

October 2025

Primary completion

October 2027

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov